Diagnosis and Classification of Myelodysplastic Syndrome by Hamid, Gamal Abdul et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Diagnosis and Classification of 
Myelodysplastic Syndrome
Gamal Abdul Hamid, Abdul Wahab Al-Nehmi 
and Safa Shukry
Abstract
Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder 
characterized by morphological dysplastic changes in one or more of the major 
hematopoietic cell lines. MDS can present with varying degrees of single or multiple 
cytopenias including neutropenia, anemia and thrombocytopenia. Presentation of 
MDS can range from asymptomatic to life threatening. MDS diagnosis and clas-
sification present important challenges, particularly in the distinction from benign 
conditions. French-American-British (FAB) classification proposed a classification 
based on easily obtainable laboratory information and was recommended in early 
and as modified by guidelines of new classification of World Health Organization 
(WHO). The strategy of diagnostic laboratory in MDS depends on morphological 
changes and is based on existence of dysplastic changes in the peripheral blood and 
bone marrow including peripheral blood smear, bone marrow aspirate smear and 
bone marrow trephine biopsy. The correct morphological interpretation and the 
use of cytogenetics, immunophenotyping, immunohistochemistry and molecular 
analysis will give valuable information on diagnosis and prognosis.
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1. Introduction
Myelodysplastic syndromes (MDS) are clonal stem cell disorders with a 
relatively heterogeneous spectrum, characterized by morphological dysplasia in 
hematopoietic cells and by bone marrow failure and varying degrees of peripheral 
blood cytopenias. MDS have been recognized for more than 70 years and named 
refractory anemia, oligoblastic leukemia and smoldering acute leukemia.
The risks of MDS include infection, anemia, bleeding and transformation to 
acute myeloblastic leukemia (AML) in approximately 30% of cases. MDS incidence 
increased from less than 5/100,000 for patients less than 60 years to 36.2 per 
100,000 in patients more than 80 year old and more common among men.
In the last 20 years, different MDS classification and prognostic scoring systems 
have been proposed [1]. French-American-British (FAB) classification was recom-
mended in early and as modified by the World Health Organization (WHO). The 
WHO classification system uses percentages of blasts in bone marrow, ring sid-
eroblasts and dysplastic changes to differentiate MDS subtypes. The International 
Prognostic Scoring System (IPSS) is based on a multivariate to evaluate the prog-
nosis. The updated and recent scoring system combine with WHO classification 
Recent Developments in Myelodysplastic Syndromes
2
for identification transfusion need was modified by Malcovati and co-workers, 
the so-called WPSS (World Prognostic Scoring System). This score suggests that 
patients with unilineage erythroid dysplasia do not need transfusion [2].
2. Diagnosis
The risk of MDS increased with advancing age; approximately 86% of patients 
with newly diagnosed MDS predominate in the elderly, with a median age at 
diagnosis 65 years [3]. The age of MDS patients at diagnosis was different according 
to residency; the results of some studies on patients show that the median age of 
diagnosis in German, Japan, and Korea were 74, 60, and 57 years, respectively [4].
The chosen diagnostic criterion of MDS is the dysplasia in ≥10% of total count, 
this morphology features can point to underlying pathological cytogenetic changes 
which suggestive MDS diagnosis according to the World Health Organization 
(WHO) 2016 revision [5].
The minimal prerequisites diagnostic guidelines for MDS according to an 
International Working Group (IWG) are: (1) stable cytopenia for >6 months unless 
accompanied a specific chromosomal analysis (Karyotype) or bilineage dysplasia 
[6]; (2) the exclusion of other potential disorders as a primary reason for dysplasia 
or cytopenia or both.
3. Diagnostic workup
MDS diagnosis based on morphological characteristics of bone marrow dysplasia 
in patients with clinical manifestations evidence of hematopoiesis impairments by 
different combinations of anemia, leukopenia, neutropenia and thrombocytopenia. 
The National Comprehensive Cancer Network (NCCN) recommend specific guide-
lines for evaluation of MDS include physical examination; peripheral blood exami-
nation, bone marrow examination with iron stain and cytogenetic, RBC folate and 
vitamin B12 and serum ferritin [7]. The combination peripheral cytopenias despite 
of bone marrow hypercellularity is the hallmark of MDS, and is a consequence of 
bone marrow dysfunction with an increase apoptosis rate of bone marrow cells.
According to NCCN the diagnosis of MDS requires ≥1 of MDS-related criteria: 
(1) dysplasia (≥10% in ≥1 of bone marrow cell line); (2) presence of 5–19% blast 
cells; and (3) presence of a specific MDS-linked chromosomal abnormalities like 
del(5q), del(20q), +8, or −7/del(7q) [8].
4. Differential diagnosis
Before treatment, the major role is to distinguish MDS from other causes of 
cytopenia and dysplastic changes and from other clonal stem cell disorders [9]. The 
investigations work-up is important to rule the possible differential diagnosis and 
pre-MDS conditions (Table 1).
4.1 Cytopenic causes
1. Chronic liver diseases
2. Drug induced cytopenia
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3. Excessive alcohol intake
4. Cytotoxic therapy
5. B12/folate deficiency
6. Autoimmune cytopenia
7. Anemia of chronic disorders
8. Parasitic manifestation (hypersplenism in malaria and leishmaniasis)
9. Human immunodeficiency virus infection (HIV)
10. Other stem cell disorder
4.2 Idiopathic cytopenia of uncertain significance (ICUS)
4.3 Idiopathic dysplasia of unknown significance (IDUS)
4.4 Clonal cytopenia of undetermined significance (CCUS)
4.5 Clonal hematopoiesis of indeterminate potential (CHIP)
5. Clinical presentation
Clinical presentation of MDS is nonspecific and varies considerably depend-
ing on subtypes and severity of cytopenias. This should include family history, 
Characteristics
IDUS Mild cytopenias for >6 months (Hb ≥ 11/dl, neutrophils ≥ 1500/μl, platelets ≥ 100,000/
μl, all below lower limit of normal) or no cytopenias but marked dysplasia in >10% of cell 
lineages and no clonal cytogenetic/molecular markers
ICUS Mild cytopenias (hemoglobin <11.0 g/dl, neutropenia <1500/μl and/or thrombocytopenia 
<100,000/μl and lack of significant dysplasia in the bone marrow but exclusion of other 
diseases and/or no clonal cytogenetic/molecular markers
CCUS Hemoglobin, <11 g/dl, ANC <1500/μl, platelet count <100,000/μl, ≥10% dysplasia in the 
granulocytic, erythroid, or megakaryocytic lineage, myeloblasts comprise ≥5% of total 
cellularity. Common mutations; TET2, DNMT3A, ASXL1, SRSF2, TP53
CHIP The presence of clonal hematopoiesis in the absence of cytopenias and dysplastic changes. 
The incidence of CHIP increases with age. Common mutations; TET2, DNMT3A, ASXL1, 
PPM1D, JAK2, TP53, SF3B1
ICUS, idiopathic cytopenia of uncertain significance; ICUS, idiopathic dysplasia of unknown significance; CCUS, 
clonal cytopenia of undetermined significance; CHIP, clonal hematopoiesis of indeterminate potential.
An absence of mutation and unexplained cytopenias are criteria do not meet World Health Organization (WHO)-defined  
requirements for myelodysplastic syndrome.
Table 1. 
Differentiation of ICUS, IDUS, CCUS and CHIP [8].
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tobacco, alcohol intake, pesticides, heavy metals, prior chemotherapy, irradiation, 
radioiodine, radioimmunotherapy, concomitant medication including “alternative 
medication”, infection, tendency for bleeding/bruising, and a complete physical 
examination including spleen size. Symptoms can include general weakness, pal-
lor, shortness of breathing, bleeding manifestations; gum bleeding and petechiae.
6. Blood tests
Complete blood count (CBC) includes white blood cell count (WBC) with differ-
ential blood count including erythrocyte morphology, hemoglobin, platelet count, 
red blood cell indices, mean corpuscular volume (MCV), and reticulocyte count.
Serum tests of erythropoietin, protein electrophoresis, folic acid, cobala-
min, iron, total iron binding capacity (TIBC), ferritin, lactate dehydrogenase 
(LDH), bilirubin, Coombs test, alanine aminotransferase (ALT) test, aspartate 
aminotransferase (AST), alkaline phosphatase, albumin, uric acid, creatinine 
(S-immunoglobulins), B2 microglobulin and thyroid function tests.
Also some investigations are mandatory to exclude viral infection especially; anti-
HIV, anti-Parvovirus B19 (hypoplastic MDS), hepatitis C antibody, hepatitis B surface 
antigen (HBsAg) and cytomegalovirus test (CMV) in transfusion dependent patients.
Cytogenetic study for BCR-ABL and JAK2 (Janus kinase 2) are important for 
differential diagnosis of myeloproliferative disorders.
6.1 Interpretation of peripheral blood
The WHO recommendations for the definition of cytopenia are the same 
reported in the International Prognostic Scoring System (IPSS), when the hemo-
globin less than 10 g/dl, the leukocyte count 3000/mm3, an absolute neutrophil less 
than 1800/mm3 and platelets less than 100,000/mm3. These thresholds have been 
a matter of debate, and as a result, any cytopenia should be differentiated from 
MDS in case of clear morphologic or the result of genetic features consistent with 
MDS [5, 6]. Anemia is represent in most patients, the mean corpuscular volume 
(MCV) is often increased and an increased erythrocyte distribution width (RDW) 
which the erythropoiesis disturbances. A dimorphic red blood cell (RBC) popula-
tion (macrocytes and microcytes), anisocytosis, poikilocytosis, nucleated red 
blood cells, basophilic stippling and Howell-Jolly bodies are also indications that 
the erythrocyte has undergone abnormal development [10]. Peripheral blood may 
reveal very abnormal nuclei such as Pelger-Huet anomalies and hypo-or hyperseg-
mentation and ring forms nuclei also occur in neutrophils are important morpho-
logical features in MDS/MPN peripheral blood when diagnosing and distinguishing 
MDS/MPN is important to understand the similarities and differences in pathologic 
mechanism from similar diseases (AML, infectious diseases and other causes of 
cytopenia). The platelet morphological changes include giant platelets and platelets 
hypogranulation or agranulation. Some platelets may possess large fused granules. 
Circulating micromegakaryocytes (dwarf cells), multiple small nuclei separated by 
strands of nuclear material, and large mononuclear cells with dysmorphic nuclear 
features have been described in peripheral blood from patients with MDS [11].
The diagnosis of MDS requires a careful light microscopic examination of opti-
mally stained peripheral blood and bone marrow smear and trephine biopsy sections 
with presence of 1% blast in peripheral blood, with <5% BM blasts and uni- or multi-
lineage dysplasia is defined as unclassifiable MDS. Monocytic hyperplasia accounting 
for >10% of the white blood cells is a common finding in chronic myelomonocytic leu-
kemia (CMML) and is a common finding in dysplastic marrows and can be dominant 
manifestation of the hematopoietic abnormality in CMML for months and years.
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7. Bone marrow aspirate and biopsy
A diagnosis of MDS often requires repeated bone marrow aspiration/biopsy exami-
nations a few weeks or months, or even years apart in order to firmly establish the 
diagnosis and to identify cases with rapid disease progression. Bone marrow morphol-
ogy evaluation and dysplasia in blood and bone marrow follow guidelines in the WHO 
2016 classification. A good quality diagnostic bone marrow analysis includes marrow 
aspirate May-Grunewald Giemsa (MGG)/equivalent and bone marrow iron stain and 
a bone marrow biopsy either decalcified/paraffin embedded or plastic embedded. 
Degree of fibrosis should be estimated. The cytochemistry staining should include iron 
staining, Peroxidase-Staining, in addition to hematoxylin-eosin/equivalent [12].
The cell counting of bone marrow and blood smear should include at least 200 
cells in blood smear, 500 cells in bone marrow and 25 megakaryocytes and at least 
100 erythroblasts should be evaluated. An optimal staining of blood and marrow 
slides prepared from freshly drawn aspirates is important for evaluation of  dysplasia 
(Table 2) [12–15].
8. Dysplastic features
Dysplastic changes are the most important diagnostic features of myelodysplas-
tic syndrome. A marrow cell lineage is considered picture of MDS if >10% of cells 
are affected.
8.1 Dyserythropoiesis
Dyserythropoiesis is the presence of oval macrocytes and erythroblast may 
resemble megaloblasts that have nuclear-cytoplasmic maturation asynchrony, 
nuclear fragmentation, or cytoplasmic nuclear remnants. This pattern is referred to 
as megaloblastoid erythropoiesis [14–16]. A dimorphic red blood cell population, 
Cell line Peripheral blood Bone marrow
Erythroid Dimorphic; macrocytic; 
anisocytosis; polychromatic; 
hypochromasia, tear drop cells 
Pappenheimer bodies; basophilic 
stippling
Erythroid hyperplasia; megaloblastic 
changes; dyserythropoiesis; multinuclearity, 
nuclear bridges, nuclear budding, atypical 
mitosis, ring sideroblasts
Granulocytes Hypersegmented neutrophils; 
hypogranular or agranular 
neutrophils; pseudo-Pelger cells
Shift to left, promyelocytes with absent or 
spares azurophilic granules; hypogranular 
myelocytes, metamyelocytes and 
neutrophils, Auer rods, pseudo-Pelger cells, 
nuclear anomalies
Monocytes Mature monocytes Increase and morphological abnormalities of 
monocytes
Megakaryocytes Thrombocytosis; giant platelets Increase or decrease; mononuclear 
megakaryocytes, micromegakaryocytes, 
hypersegmented megakaryocytes
Blasts Figure 2
The highly specific dysplastic changes in granulocytes of patients with MDS are hypoagranularity and nuclear 
abnormality of neutrophils in peripheral blood smear and positive on peroxidase reaction or Sudan black. The highly 
specific dysplastic changes in erythropoiesis are sideroblastic rings and megaloblastoid changes. The highly specific for 
dysmegakaryopoiesis are micromegakaryocytes.
Table 2. 
MDS morphology abnormalities on peripheral blood and bone marrow [12, 13].
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anisocytosis, poikilocytosis, nucleated red blood cells, Howell-Jolly bodies and 
basophilic stippling are indications that the erythrocyte has undergone abnormal 
development. The RBC with abnormally round nucleus may have lobes or buds, 
internuclear bridging, nuclear fragments and abnormal mitosis are occasionally 
present. Pathologic sideroblast may be identified when the marrow treated with 
Prussian blue stain (Figure 1) [14, 15].
8.2 Dysmyelopoiesis
The most striking abnormalities are hypogranulated neutrophils. The defect in 
granulation may be seen in myelocytes early in the course of disease. Very abnor-
mal nuclei, such as Pelger-Huet anomalies and hypo- or hypergranulation, and 
ring shaped nuclei in neutrophils. Monocytic hyperplasia is a common finding in 
dysplastic marrows and can be the dominant manifestation of the hematopoietic 
abnormalities of CMML for months or years (Figure 1) [11]. Cytoplasmic changes 
may include uneven staining such as a dense ring of basophilia around the periph-
ery with a clear unstained area around the nucleus [14, 15]. Occasionally there are 
Auer rods, either in circulating or BM blast cells, entails an unfavorable prognosis 
and this could lead to misclassification the disease in the AML. Myeloperoxidase 
and the study of specific immunophenotypic markers are helpful to differentiate 
between MDS and other types of AML [17].
Figure 1. 
Morphological abnormalities of myelodysplastic syndrome: Leishman stain. (I) Erythroid dysplastic changes; 
(A) megaloblastic changes, (B) cytoplasmic fraying, (C) internuclear bridging, (D) nuclear lobulation, 
(E) nuclear lobulation (F) karyorrhexis (II) granulocytic dysplastic changes; (G) hypogranulation band 
neutrophil, (H) pseudo-Pelger anomaly, (I) nucleus ring or doughnut shaped (III) megakaryocytic dysplastic 
changes; (J) hypersegmented, (k) micromegakaryocyte, (L) giant abnormal platelet.
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8.3 Dysmegakaryopoiesis
The common changes include giant platelets and abnormal platelet granulation, 
either hypogranulation or agranulation. Some platelets may possess large fused gran-
ules. Circulating micromegakaryocytes, multiple small nuclei separated by stands of 
nuclear material and large mononuclear cell with dysmorphic nuclear features have 
been described in peripheral blood of patients with MDS (Figure 1) [13–15].
For significant dysplasia, dysplastic features should be present in at least 10% of 
the nucleated cells in the lineage in consideration.
9. Blast cells
9.1 Counting blasts
Myeloblast cell should be differentiated from promyelocyte. The promyelocyte is 
larger than myeloblast and characterized by clear Golgi zone and azurophilic granu-
lations. Myeloblast was defined in terms of several nuclear characteristics, includ-
ing a high nuclear/cytoplasmic ratio, easily visible nucleoli and usually contain fine 
nuclear chromatin and viable nuclear shape. The International Working Group 
(IWGM) recommended that myeloblast in MDS should be classified as agranular or 
granular [12]. The agranular blast corresponds to the type I blast of the FAB classi-
fication. Type II have scanty granules [18] and type III blast with more than 20 fine 
azurophilic granules as defined by Goasguen et al. [13]. The nuclear characteristic 
of promyelocytes included an eccentric or central nucleus and intermediate or fine 
chromatin and azurophilic granulation (Figure 2) [12].
10. Cytogenetic analysis
The cytogenetic study of bone marrow aspirate has a major role in determin-
ing clonality in patients with MDS. Karyotyping should be done in all patients, at 
least 25 metaphases, whenever possible, and described according to International 
System recommendations. Chromosomal abnormalities are reported in more 
Figure 2. 
Blasts, promyelocytes, abnormal promyelocytes, modified of Mufti et al. [12]. In MDS, the granular and 
agranular blasts have azurophilic granules and Auer rods; both exhibit visible nucleoli, scant basophilic 
cytoplasm, lack Golgi zone and exist of fine nuclear chromatin, while promyelocytes have eccentric nucleus 
with visible nucleoli and Golgi zone and exist of azurophilic granules.
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than 50% of patients with MDS by counting 25 metaphase cytogenetic analysis, 
but not by fluorescence in situ hybridization (FISH) or sequencing technologies. 
The technique by using FISH method may be helpful to detect monosomy 7 and 
to clarify complex aberrations. Screening FISH (5q−, −7, +8) from peripheral 
blood may be performed in patients of dry tap bone marrow and this may influ-
ence management of the patient [19]. Different cytogenetic abnormalities are 
considered MDS-defining [20]. The presence monosomy 5, 7, or 13; 5q, 7q and 13q 
deletions; i(17p) and t(17p); 11q deletion; 9q or 12p deletion or t(12p), idic (X)
(q13) allows for the diagnosis of MDS even in the absence of dysplastic changes. 
Cytogenetic is strongly correlated with not only the calculation prognosis but also 
selection of the most effective therapy; thus, a complete BM karyotype remains 
the standard work up evaluation procedure of the patient with MDS according to 
IPSS-R (Table 3) [21, 22].
11. Molecular genetic testing
The most important mutated genes for MDS prognostication involved in epigen-
etic regulation are acquired mutation have been detected in several genes: (ASXL1, 
EZH2, DNMT3A, TET2, IDH1/2, pre-mRNA splicing factors (SF3B1, SRSF2, 
U2AF1) transcription (RUNX1, TP53) and signaling transduction are seen in MDS 
and can demonstrate clonal disease [23]. According to the new 2016 World Health 
Organization (WHO) Classification of MDS, the analysis of the SF3B1 considered 
the only important diagnostic method for diagnosis of MDS-RS. The prognosis of 
MDS-RS is favorable in presence of SF3B1 mutations [24]. Mutations in the ASXL1, 
TP53, ETV6, RUNX1 and EZH2 are reported as independently associated with 
decreased overall survival in cases of MDS [25].
12. Immunophenotyping
By flow cytometry and immunohistochemistry, immunophenotyping of the 
blast population can be useful for emerging pathological CD34 and or CD117 and 
myeloperoxidase (MPO) positive populations are suggestive of transformation.
Prognostic category Chromosomal categories Median survival 
(months)
Very good Del(11q), −Y 60
Good Normal, del(5q), double aberrations including del(5q), 
del(12p), del (20q)
40.5
Intermediate Del(7q), +8.i(17q), +19, any other 25.0
Poor Inv(3)/t(3q), −7, −7/7q, double aberrations including 
−7/7q−, complex karyotypes with 3 abnormalities
15.0
Very poor Complex karyotypes with >3 abnormalities 5.7
IPSS-R, Revised International Prognostic Scoring System.
MDS prognosis is calculated by utilizing the International Prognostic Scoring System (IPSS) score, which includes 
cytogenetics analyzed categories, in addition to number of cytopenias and counting of blast percentage. The present of 
>3 chromosomal abnormalities indicate very poor prognosis.
Table 3. 
Cytogenetic prognosis in MDS according IPSS-R [21, 22].
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According to WHO classification 2016, the best method for diagnosis of MDS 
is the percentages of blast cells in bone marrow. The immunophenotyping can be 
useful to study the expression of maturation and anomalies as marker of dysplasia 
of a particular lineage [26].
Multiple aberrant features (>3) in maturation patterns of erythroid and myeloid 
lineage are highly specific for MDS, but single aberrancies are not diagnostic [27]. 
The role of flow cytometry can be useful in the diagnostic work-up of MDS, and 
to detect minimal residual disease after treatment according to the European 
Leukemia Net (ELN) work package for flow cytometry [28]. For prognostic fol-
low up, the increase expression of CD33, CD34, CD13, HLA-DR/human leukocyte 
antigen-DR and decreased reactivity for CD11b in the bone marrow have been 
associated with shorter survival and high risk of transformation to acute leukemia.
13. Classification
13.1 FAB classification
Several classifications have been developed to predict the transformation of MDS 
to acute myeloid leukemia (AML). In 1982, the FAB system, was introduced based on 
percentage of blasts and morphological features in blood and bone marrow, namely 
medullary and peripheral blast cell count, ringed sideroblasts, number of monocytes 
in peripheral blood, and Auer rods. According to this classification, patients are 
diagnosed with MDS when dysplastic changes in bone marrow are present and/or 
myeloblast cells are between 5 and 30% of all bone marrow cells. Five subgroups 
with significantly different prognoses were established: refractory anemia (RA) with 
blasts <5% in BM, refractory anemia with ringed sideroblasts (RARS) with blasts 
<5% and ring sideroblasts >15%, refractory anemia with excess of blasts between 5 
and 20% (RAEB), RAEB in transformation to acute leukemia and blast cells ranged 
between 20 and 30% (RAEB-T) and chronic myelomonocytic leukemia characterized 
by increase of peripheral blood monocytes (CMML) (Table 4) [20, 29]. For more 
than 20 years this classification served as the standard for the evaluation of MDS 
[30]. Hypercellular MDS, and MDS with bone marrow fibrosis were not recognized 
by the FAB classification [31].
Type Blasts in blood Blasts in bone marrow
1. Refractory anemia (RA) <1% Blasts <5%, ring 
sideroblastic <15%
2. Refractory anemia with ring sideroblastic 
(RARS)
<1% Blasts <5%, ring 
sideroblasts >15%
3. Refractory anemia with excess of blast (RAEB) <5% Blasts 5–20%
4. Refractory anemia with excess blast in 
transformation (RAEB-t)
<30% Blasts 20–30%
5. Chronic myelomonocytic leukemia (CMMoL) <5% with increase 
monocytes
Blasts 0–20%
AML >30% >30%
Modified of Ref. [20].
CMML, chronic myelomonocytic leukemia blast cells <20% and monocytes ≥1000/μl); RA, refractory anemia <1% 
in PB and <5% blasts in BM; RAEB, RA with excess blasts in PB <5% and 5–20% blasts in BM; RAEB-t, RAEB with 
excess blasts in transformation between 20 and 30%; RARS, RA with ringed sideroblasts >15%.
Table 4. 
Myelodysplastic syndrome (MDS) according to FAB classification [20].
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2008 WHO classification 2016 WHO classification
Refractory cytopenia with unilineage dysplasia (RCUD) 
encompassing refractory anemia (RA), refractory 
neutropenia (RN), and refractory thrombocytopenia (RT)
MDS with single lineage dysplasia 
(MDS-SLD)
Refractory cytopenia with multilineage dysplasia (RCMD) MDS with multilineage dysplasia 
(MDS-MLD)
Refractory anemia with ringed sideroblasts (RARS) MDS with ring sideroblasts (MDS-RS)
MDS-RS with single lineage dysplasia 
(MDS-RS-SLD)
MDS-RS with multilineage dysplasia 
(MDS-RS-MLD)
Myelodysplastic syndrome associated with isolated del(5q) MDS with isolated del(5q)
MDS with excess blasts (MDS-EB)
Refractory anemia with excess blasts-1 (RAEB-1) MDS-EB-1
Refractory anemia with excess blasts-2 (RAEB-2) MDS-EB-2
Myelodysplastic syndrome, unclassified (MDS-U) MDS, unclassifiable (MDS-U)
With 1% blood blasts
With single lineage dysplasia and 
pancytopenia
Based on defining cytogenetic abnormality
Refractory cytopenia of childhood Refractory cytopenia of childhood
WHO, World Health Organization; MDS, myelodysplastic syndromes; RS, ring sideroblasts; RCUD, refractory 
cytopenia with unilineage dysplasia; RCMD, refractory cytopenia with multilineage dysplasia; MDS-MLD, MDS 
with multilineage dysplasia; MDS-SLD, MDS with single lineage dysplasia; MDS-EB, MDS with excess blasts;  
MDS-U, MSD, unclassifiable; RCC, refractory cytopenia of childhood.
Table 5. 
World Health Organization (WHO) classifications of myelodysplastic syndromes [20, 22].
13.2 WHO classification
The World Health Organization (WHO) classification of MDS revised in 1999 
and redefine subtypes of MDS [32]. The definitions of refractory anemia (RA) and 
refractory anemia with ring sideroblastic (RARS) unchanged became more consis-
tent and characterized by the presence of dysplastic morphology in the erythroid 
cell line. Refractory anemia with ring sideroblastic (RARS) is morphologically 
similar to RA with the presence of ≥15% ring sideroblasts.
Refractory anemia with excess of blasts (RAEB) recognized by the World Health 
Organization (WHO) classification in all versions and remains unchanged but 
distinguishes between two categories of RAEB: RAEB-1 with 5–10% blast cells and 
RAEB-2 with 11–20% blasts in the bone marrow.
The other new subgroups of MDS were incorporated: (1) refractory cytopenia 
with multilineage dysplasia (RC1Dys), is a frequent subtype of MDS, which is 
equivalent to RA or RARS in the FAB classification with the presence of dysplasia 
but lacking an increase in blast cells with no Auer rods or increase of monocytes; 
(2) del (5q) syndrome is a myelodysplastic disorder characterized by macrocytic 
anemia, dysplastic changes in the erythroid cell line only, thrombocytosis and 
increase of hypolobulated micromegakaryocyte; (3) MDS unclassifiable; myelodys-
plastic syndromes that do not meet criteria of a specific WHO entity.
RAEB-T and CMML subgroups were removed from the new MDS classification: 
RAEB-T, because of distinctive biologic features and similarities in treatment strate-
gies with acute myeloid leukemia (AML), and CMML, because of having overlap-
ping dysplastic and proliferative features and its close relation to myeloproliferative 
diseases [33].
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In 2001, the WHO proposed an alternative classification for MDS that was modi-
fied from the original French-American-British (FAB) definitions [18]. Since then, 
the WHO classification has been updated twice (2008 and 2016) (Table 5) [22, 33].
The last edition of WHO classification guidelines identify 6 types of MDS: MDS 
with single lineage dysplasia (MDS-SLD); MDS with ring sideroblasts (MDS-RS); 
MDS with multilineage dysplasia; MDS with excess blasts (MDS-EB); MDS with 
isolated del(5q); and MDS unclassifiable (MDS-U). There is an additional pro-
visional entity termed “refractory cytopenia of childhood.” MDS-SLD includes 
refractory anemia (unilineage erythroid dysplasia), refractory neutropenia (unilin-
eage dysgranulopoiesis), and refractory thrombocytopenia (unilineage dysmega-
karyocytopoiesis). The latter 2 were previously classified as MDS-U in 2001 but 
were reclassified in the 2008 update [34].
According to 2016 WHO classification guidelines identify MDS subtypes based 
on the results of blood and bone marrow test. The classification of 2016 WHO of 
MDS was according to factors that differ from those of the FAB system and defined 
by precise criteria including: (1) dysplastic changes (2) number of cytopenia in 
peripheral blood (3) percentage of sideroblastic rings (Table 6) [5].
13.2.1 MDS with single lineage dysplasia (MDS-SLD)
One dysplastic lineage with dysplasia in at least 10% of the early cells of 2 or 3 
cell types (red blood cells, white blood cells, and/or megakaryocytes in the bone 
marrow. No Auer rodes blast cells less than 5% in BM and <1% in PB. Sideroblastic 
ring less than 15% in BM and <5% in PB.
Subtype Blood Bone marrow
(1) MDS with single lineage 
dysplasia (MDS-SLD)
Single of bicytopenia Dysplasia in ≥10 of one cell line, <5% 
blasts
(2) MDS with ring sideroblasts 
(MDS-RS)
Anemia, no blasts ≥15% of erythroid precursors w/
ring sideroblasts, or ≥5% of ring 
sideroblasts, <5% blasts
(3) MDS with multilineage 
dysplasia (MDS-MLD)
Cytopenia(s*), <1 or 109/l 
monocytes
Dysplasia in ≥10 of cells in ≥2 
hematopoietic lineages, ±15% ring 
sideroblasts, <5% blasts
(4.1) MDS with excess blasts-1 
(MDS-EB-1)
Cytopenia(s), ≤2–4% 
blasts#, <1 × 109/l 
monocytes
Unilineage or multilineage dysplasia, 
5–9% blasts, no Auer rods
(4.2) MDS with excess blasts-2 
(MDS-EB-2)
Cytopenia(s), 5–19% 
blasts#, <1 × 109/l 
monocytes
Unilineage or multilineage dysplasia, 
10–19% blasts, ±Auer rods
(5) MDS with isolated del(5q) Anemia, platelets normal 
or increased
Unilineage erythroid dysplasia, isolated 
del(5q), <5% blasts
(6) MDS, unclassifiable 
(MDS-U)
Cytopenia(s), +1% blasts 
on at least 2 occasions
Unilineage dysplasia or no dysplasia 
but characteristic MDS cytogenetics, 
<5% blasts
(7) Refractory cytopenia of 
childhood
Cytopenias, <2% blasts Dysplasia in 1–3 lineages, <5% blasts
*Cytopenias defined as: hemoglobin, 10 g/dl; absolute neutrophil count, 1800/mm3 and platelet count less than 
100,000/mm3; S; bicytopenia may be observed in most cases of MDS.
#Present of 5–9% myeloblast in BM and 2–4% myeloblasts in the blood, the diagnostic is MDS-EB-1 and 10–19% 
myeloblast in BM and 5–19% myeloblasts in the blood, the diagnostic is MDS-EB-2. Cases with pancytopenia with 
unilineage or absent dysplasia with 1% myeloblasts in the blood should be classified as MDS-U.
Table 6. 
Peripheral blood and bone marrow findings according to 2016 WHO classification of MDS [5, 20].
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13.2.2 MDS with ring sideroblasts (MDS-RS)
MDS-RS previously named as refractory anemia with ring sideroblasts (RARS). In 
this type of MDS, there is increased sideroblastic rings of nucleated red blood and for 
diagnosis, ring sideroblasts seen in nucleated red blood cells or at least 5% if the cells 
also have high of SF3B1 mutations [35]. Mutations in SF3B1 are seen in ≥80% of cases.
MDS-RS include 2 subtypes based on dysplastic bone marrow:
• MDS-RS with single lineage dysplasia (MDS-RS-SLD): one dysplastic lineage, 
one or two PB cytopenia, sideroblastic rings >15% in BM or 5% in cases with 
SF3B1 mutation, blast cells <5% in BM and <1% in PB and no Auer rods.
• MDS-RS with multilineage dysplasia (MDS-RS-MLD): dysplasia in more 
than one lineage, one to three PB cytopenias, sideroblastic ring in BM 15 
and 5% if SF3B1 mutation is present. Blast cells in BM <5% and in PB <1% 
without Auer rods.
This type of MDS is not common. It rarely turns into AML, and the outcome for 
people with this type is generally better than for some other types of MDS.
13.2.3 MDS with multilineage dysplasia (MDS-MLD)
Dysplastic changes in two or three lineages and PB cytopenia in one to three 
lineages, sideroblastic ring in 15% in BM or 5% in cases with SF3B1 mutation, blast 
cell without Auer rods <5% in BM and <1% in PB.
13.2.4 MDS with excess blasts (MDS-EB)
In this type of MDS, the blasts are present in the bone marrow and/or peripheral 
blood. Dysplastic changes present in one to three lineage and cytopenia in one to 
three lines. Sideroblastic ring not present.
There are 2 types, based on how many of the cells in the bone marrow or blood 
are blasts:
• MDS with excess blasts-1 (MDS-EB1): blast cells make up 5–9% in the bone 
marrow aspirate, or 2–4% of blast cells in peripheral blood and absent of Auer 
rods.
• MDS with excess blasts-2 (MDS-EB2): previously named refractory anemia 
with excess blasts (RAEB), characterized by excess blasts 10–19% of bone 
marrow aspirate cells, or 5–19% blast cells in peripheral blood and/or present 
of Auer rods.
13.2.5 MDS with isolated del(5q)
“5q− syndrome” is a specific type of myelodysplastic syndrome (MDS). Is not 
common and it occurs most often in older women. It is characterized by missing 
part of chromosome number 5. The patient also has cytopenia in one or two blood 
cell lines with common manifestations including severe anemia, typical dysmega-
karyopoiesis, frequent thrombocytosis and favorable outcome [5]. The median 
survival of patients with isolated  5q– syndrome of 9 years and they have good 
prognosis and  rarely transform to develop AML [35].
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13.2.6 MDS, unclassifiable (MDS-U)
This type of MDS is uncommon. For MDS-U, the pathological findings in bone 
marrow more than in peripheral blood. We observe that, one or more cytopenias are a 
standard feature of MDS-U but other clinical features are variable. Dysplastic changes 
in bone marrow in less than 10% but typical cytogenetic abnormality was reported [5].
13.2.7 Refractory cytopenia of childhood
Usually hypocellular with similar picture of aplastic anemia. The mutations 
are less common than in adult MDS (24% of patients) and have a different profile 
NRAS/KRAS, SETBP1, ASXL1, RUNX1, BCOR/BCORL, PTPN.
14. Chronic myelomonocytic leukemia (CMML)
14.1 Definition
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem 
cell disorder classified by the WHO as an overlapping feature of myelodysplastic 
syndromes and myeloproliferative neoplasms (MPN). It is characterized by periph-
eral blood monocytosis, dysplastic features in at least 1 hematopoietic cell line and 
increased risk of progression to AML [36].
The disease annual incidence became stable at around 0.4 per 100,000 popu-
lation in Western countries [37]. CMML is occurring in elderly patients whose 
median age at diagnosis is 71–75 years. The incidence of CMML was higher in men 
than in women whose origin remains unclear [37].
14.2 Diagnosis of CMML
Diagnosis is based on the presence of sustained (>3 months) peripheral blood 
monocytosis (≥1 × 109/l; monocytes ≥10%), along with bone marrow dysplastic 
changes. Bone marrow and BCR-ABL are recommended to exclude acute leukemia and 
a classic myeloproliferative neoplasms. Atypical monocytes differ from promonocytes 
and monoblasts. They contain no nucleolus, exhibit swelling, abnormally folded nuclei, 
aggregated chromatin, nucleus-cytoplasm asynchrony. Their presence is usually associ-
ated with increase of neutrophils and shift to left picture with increase of platelet count 
but the association of macrocytic anemia and thrombocytopenia are the most common 
[38]. The CMML classified into three groups/categories for precise prognostication 
include: CMML0; a group with <2% blasts in PB and <5% blast in BM, the second 
group CMML1 include patients with 2–5% blasts in PB and 5–9% blasts in BM and 
third group include patients with 5–9% blasts in PB and 10–19% blasts in BM (Table 7) 
[5, 39].
14.2.1 Immunophenotyping of CMML
An international nomenclature has been used to help diagnose CMML [40]. 
Human monocytes can be divided into three subsets; MO1, CD14+/CD16− (classical), 
MO2, CD14+/CD16+ (intermediate) and MO3, CD14−/CD16+ (nonclassical). CMML 
is characterized by the accumulation of classical monocytes with an MO1 threshold 
to 94% of total circulating monocytes and with different gene expression profiles, 
chemokine receptor expressions and phagocytic activities [41].
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14.2.2 Cytogenetic abnormalities of CMML
Clonal cytogenetic abnormalities identify non-specific chromosomal abnormali-
ties in 30–40% of CMML patients. Peripheral blood/bone marrow for BCR-ABL 
rearrangement for all patients should be done to exclude any pathological disorder 
related to myeloproliferative disorders and PDGFRA, PDGFRB, FGFR1 rearrange-
ments or PCM1-JAK2 (Table 7) [5, 42]. The most common alterations include; 
trisomy 8 (4–11%),—Y (5–20%), abnormalities of chromosome 7 (monosomy 7 and 
del7q) in 2–14%, trisomy 21, and complex karyotypes [43].
15. Conclusions
Myelodysplastic syndrome diagnosis based on data accumulated since the 2008 
WHO classification of MDS, much of which relates to adequate medical informa-
tion, cytomorphology and dysplastic assessment and new molecular genetic infor-
mation about these neoplasms. The revised WHO classification is the more accurate 
classification introduces refinements in morphologic interpretation and cytopenia 
assessment and addresses the influence of genetic information in MDS diagnosis 
and classification of patients and will allow for better guidance of treatment.
The evaluation of cytogenetic results is important for the classification and 
determination of the prognosis according to the revised International Prognostic 
Scoring System (IPSS-R). Immunophenotyping and molecular analysis will provide 
valuable information on diagnosis and prognosis.
Persistent monocytosis ≥1 × 109/l and monocytes ≥10% of WBC in peripheral blood
<20% blasts in peripheral blood and bone marrow aspiration*
No criteria and no previous history of CML, ET**, PV, and PMF
If eosinophilia, no PDGFRA, PDGFRB, FGFR1 rearrangement, no PMC1-JAK2 fusion gene
≥1 following criteria:
1. Acquired clonal cytogenetic or molecular abnormality in hematopoietic cells***
2. Dysplasia in ≥1 myeloid lineage
3. Monocytosis persistent for at least 3 months, with other causes excluded
CML, chronic myeloid leukemia; ET, essential thrombocythemia; PV, polycythemia vera; PMF, primary 
myelofibrosis; WBC, white blood cell.
*Total blast cells include monoblast, promonoblasts and myeloblasts.
**Exclude of myeloproliferative neoplasms (MPN) associated with monocytosis by bone marrow cytology and/or of 
MPN-associated mutations (JAK2, calreticulin gene “CALR”, or myeloproliferative leukemia mutation “MPL”) tend 
to confirm the diagnosis of MPN with monocytosis rather than chronic myelomonocytic leukemia (CMML).
***The mutations associated with CMML which may support confirmation of diagnosis like ASXL1, SRSF2, SETBP1, 
TET2.
Table 7. 
Diagnostic criteria of CMML modified according to Daniel Arber of 2016 WHO classification Blood 2016 [5].
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